Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection.
Retroviruses can establish persistent infection despite induction of a multipartite antiviral immune response. Whether collective failure of all parts of the immune response or selective deficiency in one crucial part underlies the inability of the host to clear retroviral infections is currently uncertain. We examine here the contribution of virus-specific CD4(+) T cells in resistance against Friend virus (FV) infection in the murine host. We show that the magnitude and duration of the FV-specific CD4(+) T-cell response is directly proportional to resistance against acute FV infection and subsequent disease. Notably, significant protection against FV-induced disease is afforded by FV-specific CD4(+) T cells in the absence of a virus-specific CD8(+) T-cell or B-cell response. Enhanced spread of FV infection in hosts with increased genetic susceptibility or coinfection with Lactate dehydrogenase-elevating virus (LDV) causes a proportional increase in the number of FV-specific CD4(+) T cells required to control FV-induced disease. Furthermore, ultimate failure of FV/LDV coinfected hosts to control FV-induced disease is accompanied by accelerated contraction of the FV-specific CD4(+) T-cell response. Conversely, an increased frequency or continuous supply of FV-specific CD4(+) T cells is both necessary and sufficient to effectively contain acute infection and prevent disease, even in the presence of coinfection. Thus, these results suggest that FV-specific CD4(+) T cells provide significant direct protection against acute FV infection, the extent of which critically depends on the ratio of FV-infected cells to FV-specific CD4(+) T cells.
Pike
Rebecca
R
Division of Immunoregulation, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom.
Filby
Andrew
A
Ploquin
Mickaël J-Y
MJ
Eksmond
Urszula
U
Marques
Rute
R
Antunes
Inês
I
Hasenkrug
Kim
K
Kassiotis
George
G
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D005622:Friend murine leukemia virus / Q000276:immunology*; D007772:Lactate dehydrogenase-elevating virus / Q000276:immunology; D007942:Leukemia, Experimental / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology*; D051379:Mice; D008822:Mice, Transgenic; D011947:Receptors, Antigen, B-Cell / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology; D017471:Receptors, Interferon / Q000235:genetics / Q000276:immunology; D012192:Retroviridae Infections / Q000276:immunology*; D014412:Tumor Virus Infections / Q000276:immunology*; D000096743:Interferon gamma Receptor
D011947:Receptors, Antigen, B-Cell; D011948:Receptors, Antigen, T-Cell; D017471:Receptors, Interferon; D000096743:Interferon gamma Receptor
J Exp Med. 1981 Sep 1;154(3):952-63
6974221
Blood. 2000 Dec 1;96(12):3675-80
11090047
Eur J Immunol. 1998 Jan;28(1):390-400
9485218
J Virol. 1992 Jun;66(6):3271-7
1374804
J Immunol. 2008 Dec 15;181(12):8568-75
19050276
J Virol. 2008 Dec;82(24):12432-40
18842712
J Virol. 2004 Jul;78(13):6827-35
15194758
Curr Top Microbiol Immunol. 1989;148:1-42
2684547
J Virol. 2007 Nov;81(22):12535-42
17652379
J Virol. 2005 Aug;79(16):10514-27
16051844
J Virol. 1998 Aug;72(8):6559-64
9658100
J Virol. 2001 Apr;75(7):3152-63
11238842
Science. 1993 Sep 10;261(5127):1448-51
8367726
Immunity. 2000 Jun;12(6):677-86
10894167
J Exp Med. 1998 Mar 2;187(5):693-702
9480979
Trends Immunol. 2006 Jun;27(6):274-81
16679064
Nat Immunol. 2005 Sep;6(9):873-9
16116467
Eur J Immunol. 1995 Apr;25(4):1109-12
7737281
Cell. 1991 Sep 6;66(5):1051-66
1909605
Trends Immunol. 2006 Mar;27(3):119-24
16458605
Nature. 2002 May 2;417(6884):95-8
11986671
Immunity. 1998 Oct;9(4):449-57
9806631
J Virol. 2000 Aug;74(16):7422-30
10906195
Eur J Immunol. 1994 Sep;24(9):2213-8
7916297
Blood. 2007 Jun 15;109(12):5346-54
17327412
Int Immunol. 2006 Jan;18(1):183-98
16352628
Vaccine. 2008 Jun 6;26(24):2981-96
18255203
Blood. 2007 Dec 1;110(12):3949-58
17699743
J Immunol. 2006 Dec 15;177(12):8851-9
17142788
Annu Rev Immunol. 1999;17:625-56
10358770
Nat Med. 1999 Feb;5(2):189-93
9930867
Science. 2008 Sep 5;321(5894):1343-6
18772436
J Immunol. 2002 Aug 1;169(3):1593-603
12133989
J Exp Med. 1985 May 1;161(5):1122-34
3921652
Curr Opin Immunol. 2006 Aug;18(4):399-405
16753288
Virology. 1983 May;127(1):134-48
6305011
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8633-8
10411927
Infect Immun. 2007 Apr;75(4):1545-55
17283094
J Natl Cancer Inst. 1978 Jan;60(1):239-42
564410
Curr Opin Immunol. 2000 Aug;12(4):381-6
10899031
J Virol. 2008 Jan;82(1):408-18
17959678
Immunity. 2008 Nov 14;29(5):782-94
19006695
J Exp Med. 2006 Dec 25;203(13):2865-77
17158960
J Virol. 1999 Aug;73(8):6468-73
10400741
J Immunol. 2008 Sep 1;181(5):3432-40
18714015
J Immunol. 1995 Jul 15;155(2):748-58
7541823
Science. 1997 Nov 21;278(5342):1447-50
9367954
J Virol. 2008 Oct;82(19):9678-88
18667492
Nat Med. 2006 Mar;12(3):289-95
16520776
Science. 1993 Mar 19;259(5102):1742-5
8456301
J Immunol. 1979 Oct;123(4):1822-8
314476
Nat Immunol. 2004 Sep;5(9):934-42
15300247
J Virol. 2001 Jan;75(1):52-60
11119573
Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13026-31
15326293
J Immunol. 2002 Sep 15;169(6):3191-9
12218137
J Immunol. 2006 Sep 1;177(5):2888-98
16920924
Nature. 1995 May 11;375(6527):148-51
7753171
J Exp Med. 1995 Dec 1;182(6):1727-37
7500017
Rev Sci Tech. 1998 Apr;17(1):269-77
9638816
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7811-6
9223268
J Immunol. 2005 Jan 15;174(2):614-8
15634878
Immunity. 1996 Apr;4(4):337-47
8612128